News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Berk Goktepe

Articles by Berk Goktepe

84 Exceptional Responders in De Novo Metastatic Breast Cancer (dnMBC) Drug Cessation in Patients With HER2-Positive Metastatic Breast Cancer; Multicenter Retrospective Study

ByMutlu Dogan,Berk Goktepe,Mehmet Bilici,Sercan Aksoy,Fatih Selcukbiricik,Ali Alkan,Arzu Oguz,Arzu Yasar,Naziye Ak,Betul Ersoz,Lutfi Dogan,Merve Tokocin,Yasemin Evlendi,Ozlem Soran,Qurat Ul Ain Sabih,Julia Foldi,Atilla Soran, MD, MPH

June 6th 2026

Extended drug cessation appears feasible in exceptional responders with HER2+ de novo metastatic breast cancer, with significantly better survival compared with non-exceptional responders.

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

ByAttilla Soran,Berk Goktepe,Berkay Demirors,Serdar Ozbas,Efe Sezgin,Jamila Al-Azhri,Shruti Zaveri,S. Meas,Anthony Lucci, MD,Priscilla F. Mcauliffe, MD, PhD

April 21st 2024

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Afami-cel in Metastatic Synovial Sarcoma

The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word

Current Treatment Landscape of HER2-Positive Metastatic Breast Cancer and Phase 3 Trial Overview

How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?

TROPION-Breast01 and Comparative ADC Data